Literature DB >> 22414579

Systems biology of tumor dormancy: linking biology and mathematics on multiple scales to improve cancer therapy.

Heiko Enderling1, Philip Hahnfeldt, Lynn Hlatky, Nava Almog.   

Abstract

For many decades, it has been appreciated that tumor progression is not monotonic, and development of a cancer cell does not equate to inevitable cancer presentation in the clinic. Tumor progression is challenged by numerous intrinsic and extrinsic bottlenecks that can hold the tumor in dormant stages for prolonged periods. Given the complex, multiscale nature of these bottlenecks, the Center of Cancer Systems Biology organized a workshop on critical issues of systems biology of tumor dormancy. The program for the meeting this past July, chaired by N. Almog and H. Enderling, included discussions and interactive breakout sessions on regulation of tumor dormancy by angiogenesis, tumor-immune system interactions, cancer stem cell kinetics, and cell signaling pathways. Three important conclusions emerged from the meeting. The first was the urgent need to differentiate between tumor cell and tumor population dormancy of the primary tumor and metastatic deposits, the second was the continued need for interdisciplinary dialogs, and the third was the need to bring cross-scale mechanistic thinking to the field to achieve a more robust understanding of tumor dormancy and its clinical implications. ©2012 AACR

Entities:  

Mesh:

Year:  2012        PMID: 22414579      PMCID: PMC3374524          DOI: 10.1158/0008-5472.CAN-11-3269

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis.

Authors:  Nava Almog; Vanessa Henke; Ludmila Flores; Lynn Hlatky; Andrew L Kung; Renee D Wright; Raanan Berger; Lloyd Hutchinson; George N Naumov; Elise Bender; Lars A Akslen; Eike-Gert Achilles; Judah Folkman
Journal:  FASEB J       Date:  2006-04-25       Impact factor: 5.191

2.  MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.

Authors:  Dean W Felsher
Journal:  Genes Cancer       Date:  2010-06

Review 3.  Does tumour dormancy offer a therapeutic target?

Authors:  Paul E Goss; Ann F Chambers
Journal:  Nat Rev Cancer       Date:  2010-11-04       Impact factor: 60.716

Review 4.  ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease.

Authors:  Maria Soledad Sosa; Alvaro Avivar-Valderas; Paloma Bragado; Huei-Chi Wen; Julio A Aguirre-Ghiso
Journal:  Clin Cancer Res       Date:  2011-06-14       Impact factor: 12.531

5.  Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells.

Authors:  M Masiero; S Minuzzo; I Pusceddu; L Moserle; L Persano; V Agnusdei; V Tosello; G Basso; A Amadori; S Indraccolo
Journal:  Leukemia       Date:  2011-01-25       Impact factor: 11.528

6.  Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150.

Authors:  Margherita Ghisi; Alberto Corradin; Katia Basso; Chiara Frasson; Valentina Serafin; Subhamoy Mukherjee; Lara Mussolin; Katia Ruggero; Laura Bonanno; Alessandro Guffanti; Gianluca De Bellis; Gino Gerosa; Giovanni Stellin; Donna M D'Agostino; Giuseppe Basso; Vincenzo Bronte; Stefano Indraccolo; Alberto Amadori; Paola Zanovello
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

7.  Notch3 signalling promotes tumour growth in colorectal cancer.

Authors:  Valentina Serafin; Luca Persano; Lidia Moserle; Giovanni Esposito; Margherita Ghisi; Matteo Curtarello; Laura Bonanno; Massimo Masiero; Domenico Ribatti; Michael Stürzl; Elisabeth Naschberger; Roland S Croner; Adrian M Jubb; Adrian L Harris; Hartmut Koeppen; Alberto Amadori; Stefano Indraccolo
Journal:  J Pathol       Date:  2011-05-19       Impact factor: 7.996

8.  Ligand-driven activation of the notch pathway in T-ALL and solid tumors: why Not(ch)?

Authors:  Stefano Indraccolo; Sonia Minuzzo; Massimo Masiero; Alberto Amadori
Journal:  Cell Cycle       Date:  2010-01-01       Impact factor: 4.534

9.  Identification of cells initiating human melanomas.

Authors:  Tobias Schatton; George F Murphy; Natasha Y Frank; Kazuhiro Yamaura; Ana Maria Waaga-Gasser; Martin Gasser; Qian Zhan; Stefan Jordan; Lyn M Duncan; Carsten Weishaupt; Robert C Fuhlbrigge; Thomas S Kupper; Mohamed H Sayegh; Markus H Frank
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962

Review 10.  Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch.

Authors:  Dean W Felsher
Journal:  Lymphat Res Biol       Date:  2008       Impact factor: 2.589

View more
  10 in total

Review 1.  Systems biology for molecular life sciences and its impact in biomedicine.

Authors:  Miguel Ángel Medina
Journal:  Cell Mol Life Sci       Date:  2012-08-19       Impact factor: 9.261

2.  Mathematical models of immune-induced cancer dormancy and the emergence of immune evasion.

Authors:  Kathleen P Wilkie; Philip Hahnfeldt
Journal:  Interface Focus       Date:  2013-08-06       Impact factor: 3.906

3.  A new kink in an old theory of carcinogenesis.

Authors:  Richmond T Prehn; Liisa M Prehn
Journal:  Theor Biol Med Model       Date:  2013-02-18       Impact factor: 2.432

4.  Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical Implications.

Authors:  Xin Dong; Hui Xue; Fan Mo; Yen-Yi Lin; Dong Lin; Nelson K Y Wong; Yingqiang Sun; Scott Wilkinson; Anson T Ku; Jun Hao; Xinpei Ci; Rebecca Wu; Anne Haegert; Rebecca Silver; Mary-Ellen Taplin; Steven P Balk; Joshi J Alumkal; Adam G Sowalsky; Martin Gleave; Colin Collins; Yuzhuo Wang
Journal:  Mol Cancer Res       Date:  2022-05-04       Impact factor: 6.333

5.  Hypothermia activates adipose tissue to promote malignant lung cancer progression.

Authors:  Gangjun Du; Bei Zhao; Yaping Zhang; Ting Sun; Weijie Liu; Jiahuan Li; Yinghui Liu; Yingying Wang; Hong Li; Xidong Hou
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

6.  Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer.

Authors:  Hideki Kimura; Yukiko Matsui; Aki Ishikawa; Takahiro Nakajima; Mitsuru Yoshino; Yuichi Sakairi
Journal:  Cancer Immunol Immunother       Date:  2014-09-28       Impact factor: 6.968

7.  An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia.

Authors:  Kerri-Ann Norton; Travis Wallace; Niranjan B Pandey; Aleksander S Popel
Journal:  BMC Syst Biol       Date:  2017-07-11

Review 8.  Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis.

Authors:  Mohit Kumar Jolly; Marcelo Boareto; Bin Huang; Dongya Jia; Mingyang Lu; Eshel Ben-Jacob; José N Onuchic; Herbert Levine
Journal:  Front Oncol       Date:  2015-07-20       Impact factor: 6.244

9.  In silico modeling for tumor growth visualization.

Authors:  Fleur Jeanquartier; Claire Jean-Quartier; David Cemernek; Andreas Holzinger
Journal:  BMC Syst Biol       Date:  2016-08-08

Review 10.  Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening.

Authors:  Antonella Sistigu; Martina Musella; Claudia Galassi; Ilio Vitale; Ruggero De Maria
Journal:  Front Immunol       Date:  2020-10-21       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.